Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz

February 9, 2024
Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared HolzAmgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz

Jared Holz, Mizuho, joins ‘Closing Bell Overtime’ to talk Amgen’s obesity drug trial results.


 

Share This

Latest Mizuho News

Mizuho Americas and Pursuit Launch AI Nonprofit Build Corps

Mizuho Americas and Pursuit Launch AI Nonprofit Build Corps

February 11, 2026
Novo Nordisk is being more cautious on Medicare, says Mizuho’s Holz

Novo Nordisk is being more cautious on Medicare, says Mizuho’s Holz

February 4, 2026
Paypal’s network value is still huge following leadership shuffle, says Mizuho’s Dan Dolev

Paypal’s network value is still huge following leadership shuffle, says Mizuho’s Dan Dolev

February 3, 2026

Mizuho news from around the globe

back-to-top-blue